Holen Sie sich die Stockscreener-App
8.29
1.43%
-0.12
Handel nachbörslich:
8.29
Bridgebio Oncology Therapeutics Inc Aktie (BBOT) Neueste Nachrichten
BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) officer reports tax-withheld RSU share disposition - Stock Titan
Tax withholding trims BridgeBio Oncology (BBOT) CEO Beltran’s share count - Stock Titan
Form 13D/A BridgeBio Oncology Therapeutics For: 6 July By Investing.com - Investing.com Canada
Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up - Stock Titan
Cormorant funds tied to BBOT (NASDAQ: BBOT) receive 4.53M shares in internal distribution - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Oncology Therapeutics (BBOT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT - TradingView
Price to sales forward of BridgeBio Oncology Therapeutics, Inc. – BOATS:BBOT - TradingView
BridgeBio Oncology Therapeutics, Inc. Actuals & Estimates (NASDAQ:BBOT) - TradingView
BBOT Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Oncology (BBOT) Faces Selling Pressure Amid Sector Rotation ConcernsDonchian Channel - dars.gov.et
BBOT Assumed by Oppenheimer -- Rating Remains Outperform - GuruFocus
BridgeBio Oncology (BBOT) registers 63.05M shares for selling holders - Stock Titan
Michelle Doig resigns from BridgeBio Oncology Therapeutics board effective June 16, 2026 - TradingView
BridgeBio Oncology (NASDAQ: BBOT) reports 2026 director elections and auditor ratification - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Announces Resignation of Michelle Doig as Class I Director, Effective as of June 16, 2026 - marketscreener.com
Oppenheimer initiates BridgeBio Oncology stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer initiates BridgeBio Oncology stock rating at Outperform - Investing.com
Oppenheimer Initiates BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Announces Target Price $22 - Moomoo
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM:BBOT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Amidst Pre-Revenue StageBasic EPS Analysis - dars.gov.et
Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares - Stock Titan
BridgeBio Oncology (BBOT) director receives 31,675-share stock option grant - Stock Titan
Director at BridgeBio Oncology (BBOT) receives 7,289 stock options - Stock Titan
BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike - Stock Titan
Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT) - Stock Titan
Director at BridgeBio Oncology Therapeutics (BBOT) awarded stock options - Stock Titan
BridgeBio Oncology (BBOT) director Neil Kumar granted 31,675 stock options at $7.73 - Stock Titan
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence - TradingKey
BBOT Stock Price, Quote & Chart - ChartMill
Number of shareholders of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT - TradingView
BBOT Q1 2026 Earnings: Narrower Loss Surprises Modestly as Pre‑Clinical Pipeline ProgressesPretax Income Report - dars.gov.et
BridgeBio Oncology Therapeutics (BBOT) Climbs Nearly 4% as Support Holds FirmTotal Put Call - newsline.com
BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Advances - newsline.com
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Progresses PipelineGross Profit Margin - newsline.com
Technical Analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) - TradingView
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineEarnings Call Transcript - newsline.com
BridgeBio Oncology Therapeutics (BBOT) Slips 5.35% as Biotech Headwinds PersistVolume Breadth - newsline.com
BridgeBio Oncology Therapeutics (BBOT) Stock Trends and Sentiment 2026 - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Earnings Date and Reports 2026 - MarketBeat
BridgeBio Oncology Therapeutics Inc. (BBOT) Edges Higher Amid Sector RotationHigh Reward Trades - The Legal Advocate
BBOTBridgeBio Oncology Therapeutics Inc Stock Price and Quote - Finviz
BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Stem Stock SlideProfit Announcement - Newser
BBOT Dips Close to Lows With One Cancer Drug Update Steering Trade - Bez Kabli
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks - TipRanks
BridgeBio Oncology Therapeutics (BBOT) registers 63.05M shares for resale — supplement adds Q1 2026 10-Q - Stock Titan
BridgeBio Oncology Therapeutics, Inc.Common Stock (Nasdaq:BBOT) Stock Quote - FinancialContent
BridgeBio Oncology Therapeutics (BBOT) Reports Q1 2026 Results: Positive RAS-Pathway Cancer Drug Data, Cash Runway Into 2028 - Minichart
BridgeBio Oncology as of March 31 Cash, Cash Equivalents and Marketable Securities Totaling $388.9M >BBOT - Moomoo
BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bbot reports first quarter 2026 financial results and update on corporate progress - marketscreener.com
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
BridgeBio Oncology Therapeutics 1Q 2026: Net loss $(42.1M), EPS $(526.11) — 10-Q Summary - TradingView
[10-Q] BridgeBio Oncology Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):